Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
- Coste AT Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Kritikos A Service of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
- Li J Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Khanna N Division of Infectious Diseases and Hospital Epidemiology, University and University Hospital of Basel, Basel, Switzerland.
- Goldenberger D Division of Clinical Bacteriology and Mycology, University and University Hospital of Basel, Basel, Switzerland.
- Garzoni C Clinica Luganese Moncucco, Lugano, Switzerland.
- Zehnder C SYNLAB Suisse SA, Bioggio, Switzerland.
- Boggian K Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St.Gallen, St.Gallen, Switzerland.
- Neofytos D Service of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
- Riat A Service of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.
- Bachmann D Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Sanglard D Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Lamoth F Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. frederic.lamoth@chuv.ch.
- 2020-07-15
Published in:
- Infection. - 2020
English
Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1007/s15010-020-01475-8
- PMID 32661647
- Persistent URL
- https://sonar.ch/global/documents/34467
Statistics
Document views: 42
File downloads:
- Full-text: 0